ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors

Advanced Solid Tumors Clinical Trial

Official title:

A Phase 1 Study of CPI-1205 With Ipilimumab in Patients With Advanced Solid Tumors Followed by a Phase 2 Basket Study of CPI-1205 With Ipilimumab in Selected Tumor Types Previously Treated With PD-1 or PD-L1 Inhibitors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03525795
• Other study ID #: 1205-202
• Status: Completed
• Phase: Phase 1
• Start date: December 14, 2017
• Est. completion date: June 12, 2019

Study information

• Verified date: May 2022
• Source: Constellation Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 1/2, multi-center, open-label study of CPI-1205 + ipilimumab in patients with histologically or cytologically confirmed advanced solid tumors. This study is designed to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of CPI-1205 + ipilimumab in patients with advanced solid tumors. Patients in Phase 2 will be treated at the RP2D of CPI-1205 + ipilimumab.

This study was stopped prior to proceeding to Phase 2; no patients were enrolled in Phase 2.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: June 12, 2019
• Est. primary completion date: June 12, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age = 18 years

• Eastern Cooperative Oncology Group (ECOG) performance status 0-1

• Diagnosis and Prior Treatment:

• Phase 1: Patients with histologically or cytologically confirmed locally advanced (unresectable) or metastatic solid tumors and with progressive disease during or after treatment with a PD-1 or PD-L1-inhibitor who meet one of the following criteria:

1. Relapsed following or progressed through standard therapy

2. Have a disease for which no standard effective therapy exists (i.e., a therapy that demonstrates a significant increase in survival)

3. Not a candidate for standard effective therapy NOTE: In men with prostate cancer, baseline testosterone levels must also be =50ng/dL (= 2.0nM) and surgical or ongoing medical castration must be maintained throughout the duration of the study.

• Phase 2: Patients with histologically or cytologically confirmed diagnosis of one of the following and with progressive disease during or after treatment with a PD-1 or PD-L1-inhibitor:

1. Cohort A: unresectable or metastatic melanoma

2. Cohort B: metastatic NSCLC

3. Cohort C: advanced or metastatic (stage 4) RCC

4. Cohort D: unresectable or metastatic urothelial carcinoma (urethra, bladder, ureters, or renal pelvis)

• If patient has known brain metastases, must have stable neurologic status following local therapy for at least 4 weeks without the use of steroids or on stable or decreasing dose of =10 mg daily prednisone (or equivalent), and must be without neurologic dysfunction that would confound the evaluation of neurologic and other adverse events (AEs).

• Phase 1: patients may have measurable or non-measurable disease; measurable disease via RECIST 1.1 is required for Phase 2 patients

• Recovery from recent surgery, radiotherapy, chemotherapy or any other anti-cancer therapy to baseline or = Grade 1 (other than alopecia); = Grade 2 neuropathy allowed

• Demonstrate adequate organ function

• Ability to swallow and retain oral medications

Exclusion Criteria:

• Carcinomatous meningitis

• Prior treatment with CTLA-4 inhibitor

• Phase 2 Cohort: ocular melanoma

• Experienced an immune-related adverse event (irAE) that led to permanent discontinuation of prior immunotherapy

• History of severe hypersensitivity reaction to treatment with another monoclonal antibody

• History of interstitial lung disease, idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis on screening chest computed tomography (CT) scan; NOTE: history of radiation pneumonitis in the radiation field (fibrosis) is permitted.

• Active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)

• Known history of human immunodeficiency virus (HIV) (HIV1/2 antibodies)

• Gastrointestinal (GI) disorder that negatively affects absorption

Related Conditions & MeSH terms

• Advanced Solid Tumors
• Neoplasms

Intervention

Drug:
• CPI-1205
Administered orally
• ipilimumab
Administered intravenously

Locations

Country	Name	City	State
United States	START Midwest	Grand Rapids	Michigan
United States	The University of Texas - MD Anderson Cancer Center	Houston	Texas
United States	South Texas Oncology & Hematology	San Antonio	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Constellation Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phase 1: Frequency of Dose-limiting toxicities (DLTs)	The RP2D will be selected based on the PK, pharmacodynamics and overall tolerability of the regimen, but will not exceed the MTD.	1 year
Primary	Phase 2: Objective response rate	The rate of confirmed complete responses (CR) + partial responses (PR) as determined by RECIST 1.1 criteria	1 year
Secondary	Objective response rate	The rate of confirmed iCR + iPR	1 year
Secondary	Clinical Benefit Rate	The rate of CR + PR + stable disease (SD) after 3 months of treatment as determined by RECIST 1.1 criteria and as the rate of iCR + iPR + iSD after 3 months of treatment by iRECIST criteria	3 months
Secondary	Time to response	The time from day (D) 1 of treatment to the date of first response as determined by RECIST 1.1 and iRECIST criteria	1 year
Secondary	Duration of Response	The time from measurement criteria are first met for CR/PR or iCR/iPR (whichever is first recorded) until the date of recurrence or progressive disease as determined by RECIST 1.1 and iRECIST criteria	1 year
Secondary	Duration of treatment	The time from D1 of treatment until the date treatment is discontinued for any reason	1 year
Secondary	Progression free survival	The time from D1 of treatment to the date of progression or death, whichever occurs first with progressive disease as determined by RECIST 1.1 and iRECIST criteria	6 months
Secondary	Adverse Events	AEs will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version 4.03 (CTCAE v4.03).	1 year